Navigation Links
Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Date:8/21/2007

evelopment of LX1031 and the potential therapeutic and commercial potential of LX1031. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
4. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
5. Screening and classifying hazardous waste samples
6. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
7. Early Stage, Step 8: Misclassifying workers brings risk
8. Healthcare software addresses "90 million" misclassified Americans
9. Classroom projects translate into immediate workplace gains
10. Group promoting classified research elects officers
11. Sonic Foundry discounts Mediasite for classrooms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Pa. , Sept. 17, 2014 BioClinica®, ... and eClinical Solutions, today announced three of its experts ... for Clinical Data Management to be held September ... Nevada . The Company also announced the innovative ... raise overall quality in clinical trials acquired earlier this ...
(Date:9/17/2014)... PA & Rockville, MD (PRWEB) September 17, 2014 ... won a Small Business Innovation Research (SBIR) grant to ... immunotherapy. The award will provide ITI with approximately $255,000 ... Tree nuts, a leading cause of food allergy, affect ... cause of anaphylaxis behind peanut allergy. Tree nut exposure ...
(Date:9/17/2014)... MA (PRWEB) September 17, 2014 Terracon ... version of its TerraPure tank . This addition ... is molded from FDA-compliant linear polyethylene and available in ... pre-installed fittings and ships in two weeks or less. ... features and benefits found in Terracon’s existing TerraPure tank ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia ... quantitative data from a study of the cost and ... the 50 th Annual Meeting of the European ... poster session today, Christian Frois , Ph.D., of ... a series of planned Intarcia-sponsored, retrospective studies to characterize ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... (OTC Bulletin Board: WDSTD ), a development ... an initial $3.25 million funding in conjunction with its ... controlled by Lonza Walkersville ("Lonza Agreement").  Lonza Walkersville is ... of the world,s leading suppliers to the pharmaceutical, healthcare ...
... FutureFuel Corp. (OTC Bulletin Board: FTFL ) filed ... special cash dividend of $0.20 per share. The ... a special cash dividend of U.S. $0.20 per share on ... 2010. The dividend is payable September 30, 2010. ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ... in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key ...
Cached Biology Technology:Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville 2Shire plc - Statement re ProAmatine 2Shire plc - Statement re ProAmatine 3Shire plc - Statement re ProAmatine 4Shire plc - Statement re ProAmatine 5Shire plc - Statement re ProAmatine 6
(Date:9/17/2014)... decline, grasses have returned to some once-denuded patches of ... those places seems healthy again, but a new study ... coastal protection remains diminished. , "We,ve got ... back," said ecologist Mark Bertness, professor of biology at ... journal Biological Conservation . "The metric of a ...
(Date:9/17/2014)... faster since the 1960s. The typical development phases of ... accelerated -- by as much as 70 percent. This ... scientists from Technische Universitt Mnchen based on long-term data ... since 1870. Their findings were published recently in ... was a hot topic, with the very survival of ...
(Date:9/17/2014)... new crime unit designed to fight food fraud ... meat being passed off as beef scientists from ... They describe their approach, which represents a vast improvement ... and Food Chemistry . , Hans-Ulrich Humpf and colleagues ... problem. But they also say that adding, for example, ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... lab-made version of a human protein alleviates symptoms of ... be the basis for a new arthritis drug for ... and Infectious Disease (NIAID), part of the National Institutes ... a cell surface receptor, thus blocking transmission of chemical ...
... research with the flatworm, planaria, offers new clues ... The Forsyth Institute have discovered how the worm's ... Forsyth scientists have found that gap-junction (microscopic ... this signaling. This research, led by Dr. Michael ...
... production of a protein called vasostatin may prove a promising ... of print in Gut. , Pancreatic cancer is the fifth ... is extremely difficult to treat. Only 3% of affected patients ... that has remained static for the past three decades. , ...
Cached Biology News:Synthetic Protein Eases Arthritis Symptoms in Mice 2New understanding of regeneration gained by Forsyth scientists 2Jefferson researchers find nanoparticle shows promise in reducing radiation side effects 2
MW5...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
... GeneBLAzer cell-based assays utilize the membrane-permeant ... the negatively charged fluorescent beta-lactamase substrates, ... readily enter the cell, where cleavage ... them into their negatively charged forms, ...
Inquire...
Biology Products: